Understanding cognitive and emotional profiles in Multiple Sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the cognitive, energetic, behavioral, and affective (CEBA) profiles in individuals diagnosed with Multiple Sclerosis (MS). It focuses on identifying non-physical symptoms that significantly impact the quality of life and societal participation of patients. By conducting neuropsychological assessments, the study seeks to highlight the prevalence and interrelation of CEBA symptoms among patients with MS, which are often overlooked in traditional treatment approaches. The findings may help in recognizing these symptoms earlier and improving treatment strategies for affected individuals.

Why it matters

Who can join: the full rules

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

Inclusion Criteria:

* Confirmed MS diagnosis (all subtypes);
* Age18-70;
* Adequate command of the Dutch language.

Exclusion Criteria:

* Not being able to participate in a short neuropsychological assessment (NPA) as judged by the MS clinician and/or investigator;
* Presence of any other neurological and/or major psychiatric condition.

The group of HC's will be matched to the patient group on age and education level.

Where it's running

• University Medical Center Groningen (UMCG)
  Groningen, Provincie Groningen, Netherlands Recruiting

Study contacts

• Principal investigator: Joke Spikman, Prof. Dr. — Department of Neurology - Unit Neuropsychology of the University Medical Center Groningen (UMCG)
• Study coordinator: Anniek Reinhardt, MSc./Drs.
• Email: a.reinhardt@umcg.nl
• Phone: +3150 3619431

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treadmill-based virtual reality walking training for MS patients

  This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.

  Recruiting Shepherd Center, Atlanta GA · Atlanta, Georgia · NCT07927439

• Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS

  This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.

  Recruiting Cairo University · Giza, Giza Governorate · NCT07918339

• REAL-MS: A Look at Autologous Stem Cell Transplant vs High-Efficacy MS Therapies in Real-World Care

  This study tests how AHSCT compares to high-efficacy MS medicines in adults treated in routine clinical care.

  Recruiting Imperial College London · London and 2 other locations · NCT07899502

• Tolebrutinib in real-world MS care for patients treated by clinicians

  This real-world study sees how tolebrutinib is used for multiple sclerosis patients and what outcomes look like in everyday practice.

  Recruiting Sanofi · Marina, Abu Dhabi Emirate · NCT07898371

• Pilates via live video vs. prerecorded videos for people with multiple sclerosis

  This study tests whether live, coach-led Pilates sessions through video calls are more beneficial than prerecorded Pilates videos for adults with MS.

  Recruiting Yuzuncu Yil University · Van · NCT07893925

• Cooling During Inpatient Rehab for People with MS

  This trial tests whether wearing a cooling vest during intensive training can reduce fatigue and improve walking, strength, balance, and cognition in people with multiple sclerosis during a 3-week inpatient rehab stay.

  Recruiting Klinik Valens · Valens, Canton of St. Gallen · NCT07852156

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.